These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35640959)

  • 1. Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease.
    Kreuter M; Hoffmann-Vold AM; Matucci-Cerinic M; Saketkoo LA; Highland KB; Wilson H; Alves M; Erhardt E; Schoof N; Maher TM
    Rheumatology (Oxford); 2023 Feb; 62(SI):SI43-SI53. PubMed ID: 35640959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Divergent perspectives: exploring the relationships between St. George's Respiratory Questionnaire and outcome measures in systemic sclerosis-associated interstitial lung disease.
    Basaran E; Temiz Karadag D; Cakir O; Gokcen N; Yazici A; Cefle A
    Clin Rheumatol; 2024 May; 43(5):1647-1656. PubMed ID: 38573479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
    Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
    Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects.
    Maher TM; Bourdin A; Volkmann ER; Vettori S; Distler JHW; Alves M; Stock C; Distler O
    Respir Res; 2022 Jul; 23(1):178. PubMed ID: 35790961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis.
    Kreuter M; Del Galdo F; Miede C; Khanna D; Wuyts WA; Hummers LK; Alves M; Schoof N; Stock C; Allanore Y
    Arthritis Res Ther; 2022 Jan; 24(1):19. PubMed ID: 35012623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validity of the Saint George's Respiratory Questionnaire in the evaluation of the health-related quality of life in patients with interstitial lung disease secondary to systemic sclerosis.
    Beretta L; Santaniello A; Lemos A; Masciocchi M; Scorza R
    Rheumatology (Oxford); 2007 Feb; 46(2):296-301. PubMed ID: 16877463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial.
    Denton CP; Goh NS; Humphries SM; Maher TM; Spiera R; Devaraj A; Ho L; Stock C; Erhardt E; Alves M; Wells AU
    Rheumatology (Oxford); 2023 May; 62(5):1870-1876. PubMed ID: 36111858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis.
    Wallace B; Kafaja S; Furst DE; Berrocal VJ; Merkel PA; Seibold JR; Mayes MD; Khanna D
    Rheumatology (Oxford); 2015 Aug; 54(8):1369-79. PubMed ID: 25667436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial.
    Volkmann ER; Kreuter M; Hoffmann-Vold AM; Wijsenbeek M; Smith V; Khanna D; Denton CP; Wuyts WA; Miede C; Alves M; Sambevski S; Allanore Y
    Rheumatology (Oxford); 2022 Nov; 61(11):4397-4408. PubMed ID: 35150246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computer-Aided Tomographic Analysis of Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc). Correlation with Pulmonary Physiologic Tests and Patient-Centred Measures of Perceived Dyspnea and Functional Disability.
    Salaffi F; Carotti M; Di Donato E; Di Carlo M; Ceccarelli L; Giuseppetti G
    PLoS One; 2016; 11(3):e0149240. PubMed ID: 26930658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Distler O; Highland KB; Gahlemann M; Azuma A; Fischer A; Mayes MD; Raghu G; Sauter W; Girard M; Alves M; Clerisme-Beaty E; Stowasser S; Tetzlaff K; Kuwana M; Maher TM;
    N Engl J Med; 2019 Jun; 380(26):2518-2528. PubMed ID: 31112379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease.
    Allanore Y; Khanna D; Smith V; Aringer M; Hoffmann-Vold AM; Kuwana M; Merkel PA; Stock C; Sambevski S; Denton CP;
    Rheumatology (Oxford); 2024 Mar; 63(3):639-647. PubMed ID: 37294870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interstitial lung disease in patients with systemic sclerosis: what can we learn from the SENSCIS trial?
    Assassi S; Tumuluri S; Levin RW
    Clin Exp Rheumatol; 2023 Aug; 41(8):1713-1719. PubMed ID: 37534955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II.
    Tashkin DP; Volkmann ER; Tseng CH; Roth MD; Khanna D; Furst DE; Clements PJ; Theodore A; Kafaja S; Kim GH; Goldin J; Ariolla E; Elashoff RM
    Chest; 2017 Apr; 151(4):813-820. PubMed ID: 28012804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline absolute monocyte count predicts lung function decline among patients with systemic sclerosis-associated interstitial lung disease: A post hoc analysis from the focuSSced trial.
    Bernstein EJ; Denton CP; Huang S; Khanna D
    Semin Arthritis Rheum; 2024 Apr; 65():152376. PubMed ID: 38244446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.
    Naidu GSRSNK; Sharma SK; Adarsh MB; Dhir V; Sinha A; Dhooria S; Jain S
    Rheumatol Int; 2020 Feb; 40(2):207-216. PubMed ID: 31813058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases.
    Cheng JZ; Wilcox PG; Glaspole I; Corte TJ; Murphy D; Hague CJ; Ryerson CJ
    Respirology; 2017 Nov; 22(8):1592-1597. PubMed ID: 28544079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial.
    Kuwana M; Ogura T; Makino S; Homma S; Kondoh Y; Saito A; Ugai H; Gahlemann M; Takehara K; Azuma A
    Mod Rheumatol; 2021 Jan; 31(1):141-150. PubMed ID: 32243207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.
    Kuwana M; Allanore Y; Denton CP; Distler JHW; Steen V; Khanna D; Matucci-Cerinic M; Mayes MD; Volkmann ER; Miede C; Gahlemann M; Quaresma M; Alves M; Distler O
    Arthritis Rheumatol; 2022 Mar; 74(3):518-526. PubMed ID: 34514739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.